Lumexa Imaging Holdings earnings release, August 12, 2026

Lumexa Imaging Holdings, Inc. (LMRI) · Form 8-K, Item 2.02 · Filed · SEC filing

Lumexa Imaging Announces Second Quarter 2026 Results

RALEIGH, N. C., August 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.

“During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months.”

“With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

Second

Quarter 2026 Highlights:

All comparisons are to the quarter ended June 30, 2025, unless otherwise noted

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m. ET.

The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of

Non-GAAP

Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and

Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance;

(ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and greater than 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
REVENUES:Net patient service revenue203,735198,185
REVENUES:Management fee and other revenue60,42753,217
REVENUES:Total revenues264,162251,402
OPERATING EXPENSES:Cost of operations, excluding depreciation and amortization225,285212,265
OPERATING EXPENSES:General and administrative expenses24,39718,689
OPERATING EXPENSES:Depreciation and amortization10,0839,279
OPERATING EXPENSES:(Gain) loss on disposal of property and equipment-2416
OPERATING EXPENSES:Total operating expenses259,741240,249
OPERATING EXPENSES:Equity in earnings of unconsolidated affiliates18,61916,527
OPERATING EXPENSES:INCOME FROM OPERATIONS23,04027,680
OTHER EXPENSES:Interest expense16,22230,097
OTHER EXPENSES:Loss on extinguishment and modification of debt1,053
OTHER EXPENSES:Total other expenses17,27530,097
OTHER EXPENSES:INCOME (LOSS) BEFORE INCOME TAXES5,765-2,417
OTHER EXPENSES:Income tax provision3,0204,809
OTHER EXPENSES:NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)2,745-7,226
Weighted average shares outstanding:Basic95,983,24669,526,574
Weighted average shares outstanding:Diluted96,039,42669,526,574
Net income (loss) per common shareBasic0.03-0.1
Net income (loss) per common shareDiluted0.03-0.1

Income Statement

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
REVENUES:Net patient service revenue401,053390,483
REVENUES:Management fee and other revenue115,646105,920
REVENUES:Total revenues516,699496,403
OPERATING EXPENSES:Cost of operations, excluding depreciation and amortization443,040420,662
OPERATING EXPENSES:General and administrative expenses44,73236,181
OPERATING EXPENSES:Depreciation and amortization20,00518,330
OPERATING EXPENSES:(Gain) loss on disposal of property and equipment113-146
OPERATING EXPENSES:Total operating expenses507,890475,027
OPERATING EXPENSES:Equity in earnings of unconsolidated affiliates33,64331,845
OPERATING EXPENSES:INCOME FROM OPERATIONS42,45253,221
OTHER EXPENSES:Interest expense32,55359,946
OTHER EXPENSES:Loss on extinguishment and modification of debt1,053
OTHER EXPENSES:Total other expenses33,60659,946
OTHER EXPENSES:INCOME (LOSS) BEFORE INCOME TAXES8,846-6,725
OTHER EXPENSES:Income tax provision4,3848,188
OTHER EXPENSES:NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)4,462-14,913
Weighted average shares outstanding:Basic95,983,24069,524,980
Weighted average shares outstanding:Diluted96,011,33569,524,980
Net income (loss) per common shareBasic0.05-0.21
Net income (loss) per common shareDiluted0.05-0.21

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Net income (loss)2,745-7,226
Depreciation and amortization10,0839,279
Income tax provision3,0204,809
Amortization of basis difference573500
Interest expense16,22230,097
Stock-based compensation12,7378,346
Loss on extinguishment and modification of debt1,053
Loss (gain) on disposal of property and equipment-2416
Severance and executive recruiting(1)686803
Strategic initiatives and implementation(2)2,6591,018
Transaction costs(3)7073,875
Litigation and settlements(4)1,173
Other(5)87142
Adjustments for equity in earnings of unconsolidated affiliates(6)4,7244,615
Adjusted EBITDA56,44556,274

Income Statement

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss)4,462-14,913
Depreciation and amortization20,00518,330
Income tax provision4,3848,188
Amortization of basis difference1,1051,000
Interest expense32,55359,946
Stock-based compensation25,01114,720
Loss on extinguishment and modification of debt1,053
Loss (gain) on disposal of property and equipment113-146
Severance and executive recruiting(1)1,6312,173
Strategic initiatives and implementation(2)3,4841,886
Transaction costs(3)3,2897,464
Litigation and settlements(4)1,202-128
Other(5)82158
Adjustments for equity in earnings of unconsolidated affiliates(6)9,2708,596
Adjusted EBITDA107,644107,274

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Six Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2025
Components of “management fee and other revenues:”Fees for managing joint ventured outpatient sites and other third party services26,10320,578
Components of “management fee and other revenues:”Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa34,32432,639
Components of “management fee and other revenues:”Total revenues60,42753,217
Components of “management fee and other revenues:”Fees for managing joint ventured outpatient sites and other third party services47,60140,654
Components of “management fee and other revenues:”Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa68,04565,266
Components of “management fee and other revenues:”Total revenues115,646105,920

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026December 31, 2025
ASSETSCash and cash equivalents69,70558,828
ASSETSAccounts receivable120,637112,942
ASSETSAccounts receivable, related party20,02418,893
ASSETSOther receivables31,55219,015
ASSETSPrepaid expenses14,49817,582
ASSETSTotal current assets256,416227,260
ASSETSProperty and equipment, net of accumulated depreciation156,062144,709
ASSETSOperating lease right-of-use assets77,03376,555
ASSETSInvestments in unconsolidated affiliates423,331423,191
ASSETSIntangible assets, net of accumulated amortization39,72241,335
ASSETSGoodwill807,554807,554
ASSETSOther assets48,65443,953
ASSETSTOTAL ASSETS1,808,7721,764,557
LIABILITIES AND EQUITYAccounts payable27,06244,857
LIABILITIES AND EQUITYAccrued expenses and other current liabilities109,16795,561
LIABILITIES AND EQUITYAccounts receivable pledging arrangement1,2671,599
LIABILITIES AND EQUITYCurrent portion of long-term debt14,33013,112
LIABILITIES AND EQUITYCurrent portion of finance lease liabilities14,59711,552
LIABILITIES AND EQUITYCurrent portion of operating lease liabilities11,93212,513
LIABILITIES AND EQUITYTotal current liabilities178,355179,194
LIABILITIES AND EQUITYLong-term debt, less current maturities819,753819,029
LIABILITIES AND EQUITYLong-term finance lease liabilities, less current maturities41,17733,262
LIABILITIES AND EQUITYLong-term operating lease liabilities, less current maturities72,29671,437
LIABILITIES AND EQUITYDeferred income taxes43,59240,772
LIABILITIES AND EQUITYOther liabilities38,53834,740
LIABILITIES AND EQUITYTotal liabilities1,193,7111,178,434
EQUITY:Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,074,976 shares issued and outstanding at June 30, 2026 and 96,109,927 shares issued and outstanding at December 31, 20259696
EQUITY:Additional paid-in-capital1,241,5631,217,087
EQUITY:Accumulated deficit-626,598-631,060
EQUITY:Total equity615,061586,123
EQUITY:TOTAL LIABILITIES AND EQUITY1,808,7721,764,557

Cash Flow

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)4,462-14,913
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesDepreciation and amortization20,00518,330
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of operating lease right-of-use assets7,9567,424
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of debt issuance costs1,4372,871
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of cloud computing implementation costs760184
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesWrite-off of debt issuance costs related to extinguishment of debt46
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesEquity in earnings of unconsolidated affiliates-33,643-31,845
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesDistributions from investments in unconsolidated affiliates36,86932,820
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesLoss on disposal of property and equipment113-146
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesDeferred income taxes2,8201,477
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesStock-based compensation25,01114,720
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesOther-535
Changes in operating assets and liabilities:Accounts receivable-7,695-6,870
Changes in operating assets and liabilities:Accounts receivable, related party-1,131-2,035
Changes in operating assets and liabilities:Capitalized cloud computing implementation costs-1,647-1,421
Changes in operating assets and liabilities:Other receivables-12,537-5,410
Changes in operating assets and liabilities:Prepaid expenses3,034-7,028
Changes in operating assets and liabilities:Other assets-4,723-11,311
Changes in operating assets and liabilities:Accounts payable-18,5961,214
Changes in operating assets and liabilities:Accrued expenses and other current liabilities18,085-11,002
Changes in operating assets and liabilities:Other liabilities3,7987,018
Changes in operating assets and liabilities:Operating lease liabilities-8,156-5,966
Changes in operating assets and liabilities:Net cash provided by (used in) operating activities35,733-11,889
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from sale or disposal of property and equipment40713
CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of intangible asset-600
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment-14,985-5,602
CASH FLOWS FROM INVESTING ACTIVITIES:Contributions to investments in unconsolidated affiliates-3,366
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash used in investing activities-18,911-4,889
CASH FLOWS FROM FINANCING ACTIVITIES:Payment of third-party debt issuance costs-154
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from long-term debt9,536496
CASH FLOWS FROM FINANCING ACTIVITIES:Payments of long-term debt-8,393-7,821
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from revolving line of credit5,000
CASH FLOWS FROM FINANCING ACTIVITIES:Payments of finance lease liabilities-6,602-2,998
CASH FLOWS FROM FINANCING ACTIVITIES:Capital contributions715
CASH FLOWS FROM FINANCING ACTIVITIES:Repayments on accounts receivable pledging arrangement-332
CASH FLOWS FROM FINANCING ACTIVITIES:Net cash used in financing activities-5,945-4,608
CASH FLOWS FROM FINANCING ACTIVITIES:NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS10,877-21,386
CASH FLOWS FROM FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, beginning of period58,82826,131
CASH FLOWS FROM FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, end of period69,7054,745
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,”

“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”

“should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form

10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form

10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact

Sue Dooley

Lumexa Imaging

Sue.Dooley@LumexaImaging.com

Media Contact

Melissa Weston

Lumexa Imaging elissa.Weston@LumexaImaging.com

Lumexa Imaging Q2 2026 Outpatient Volumes Highlights:

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lumexa Imaging Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.